

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Flaherty Keith T.</u>  (Last) (First) (Middle) 11975 EL CAMINO REAL, SUITE 101  (Street) SAN DIEGO CA 91230  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/02/2020	3. Issuer Name and Ticker or Trading Symbol <u>Kinnate Biopharma Inc. [ KNTE ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	66,377	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)	09/17/2028	Common Stock	32,064	0.18	D	
Stock Option (Right to Buy)	(2)	02/05/2030	Common Stock	56,112	2.57	D	
Stock Option (Right to Buy)	(3)	08/18/2030	Common Stock	11,391	5.63	D	

**Explanation of Responses:**

- The Option vests and becomes exercisable over time at the following rate: 1/48th of the total number of shares subject to the Option shall vest monthly in equal installments over four years commencing on the one-month anniversary of June 1, 2018, the Vesting Commencement Date, and each month thereafter on the same day of the month as the Vesting Commencement Date.
- The Option vests and becomes exercisable over time at the following rate: 1/48th of the total number of shares subject to the Option shall vest monthly in equal installments over four years commencing on the one-month anniversary of December 19, 2019, the Vesting Commencement Date, and each month thereafter on the same day of the month as the Vesting Commencement Date.
- The Option vests and becomes exercisable over time at the following rate: 1/48th of the total number of shares subject to the Option shall vest monthly in equal installments over four years commencing on the one-month anniversary of August 1, 2020, the Vesting Commencement Date, and each month thereafter on the same day of the month as the Vesting Commencement Date.

**Remarks:**

Date set forth above represents the effective date of the issuer's initial public offering. Exhibit List: Exhibit 24 - Power of Attorney

/s/ Mark A. Meltz,  
attorney-in-fact

12/02/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**POWER OF ATTORNEY**

The undersigned, as a Section 16 reporting person of Kinnate Biopharma Inc. (the “Company”), hereby constitutes and appoints Nima Farzan, Mark Meltz, James Reilly, and Benjamin Capps the undersigned’s true and lawful attorneys-in-fact to:

1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned’s ownership, acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agent shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10<sup>th</sup> day of November, 2020.

Signature: /s/ Keith Thomas Flaherty

Print Name: Keith Thomas Flaherty

---